The present application seeks to study the long-term consequences of cosmic radiation exposure. Space travel increases solar particle radiation exposure which is significantly elevated once travel…

Ended Grant For Research Awarded Last action

Contract number
80NSSC19K0436
Awardee
Awarding agency
Obligated
$457,307

Award facts

Contract value 85% obligated
$540,200.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Contracting staff
NAICS code
Not on record
Set-aside
No set-aside
Competition
Full and Open Competition Basic Research
Pricing
Other
Place of performance
Valhalla, NY 10595, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action P00006 -$47,693
Other Administrative Action P00005 $0
Funding Only Action P00004 $0
Other Administrative Action P00003 $0
Funding Only Action P00002 $255,000
Funding Only Action P00001 $0
Original award $250,000

About this award

This $540,200 cost-plus-fixed-fee grant was awarded by the National Aeronautics and Space Administration Shared Services Center to New York Medical College, a subsidiary of Touro University, to study the long-term consequences of cosmic radiation exposure. Over the three-year period of performance ending January 2023, the contractor will evaluate the impact of heavy ion radiation like iron-56 and protons on cardiovascular function and identify pathways that lead to radiation-induced cardiomyopathy. The contractor will utilize cultured cells and mouse models to test the effectiveness of three countermeasures - Mitotempo, Metformin, and Lisinopril - at mitigating cellular damage, accelerated senescence, and genomic instability caused by space radiation. Findings from this research aim to improve understanding of space radiation risks and inform strategies to ensure the long-term health of crew members on deep space missions beyond low Earth orbit.

Description

The present application seeks to study the long-term consequences of cosmic radiation exposure. Space travel increases solar particle radiation exposure which is significantly elevated once travel moves beyond low earth orbit. This includes a combination of HIGH energy protons and heavy ions such as 56FE, 28SI, and 16O. The adverse risk of radiation-induced heart failure is also evident as a long-term consequence of accidental radiation exposure or cancer treatment. Survivors of cancer are also at risk for other adverse health outcomes including abnormal pulmonary function, endocrine disorders, neurocognitive impairment, and osteoporosis. All of these organ systems are characterized by a low turnover of cells and IT is likely that an accelerated cell death and/or the failure of regeneration by the pluripotent cells may be the underlying cause of organ failure. Although this application will focus on heart failure, our findings will have implications for many organ systems. Our preliminary studies observed degradation of cardiovascular function in a model of cosmic radiation (HIGH-let) exposure. Mice were exposed to 50 CGY (FE56) at 3 months of age and then studied at 24 months of age. Degradation of cardiac function was evident by significant decreases in myocardial contractility and relaxation. Concomitant with this were significant changes in mitochondrial and stem/progenitor cell function. In the present ground based application, we propose to evaluate the impact of HIGH-let; to identify the pathway to heart failure, and evaluate three distinct protocols as potential countermeasures. Hypothesis: radiation-induced cardiomyopathy is the result of a cell specific failure. Cell specific failure is the result of an inability to maintain the balance of repair/replacement that ultimately leads to activation of degradation pathways and accelerated cell loss. This study will utilize both cultured cells as well as swiss webster mice to be randomly assigned to control or single heavy ION HIGH- let exposure groups. Phase 1 will use single exposures to HIGH-let exposure of 1) 56FE (50 CGY) or 2) proton (200 CGY). Phase 2 will utilize a mixed field exposure following the guidelines of the hero announcement (80JSC017N0001-bpba; appendix C). All exposures will be performed at the NASA space radiation laboratory at brookhaven national laboratory. We plan to study three distinct countermeasures including 1) mitotempo, 2) metformin, 3) lisinopril. Mitotempo is an antioxidant that partitions to the mitochondria. Metformin, an antidiabetic mainstay, has more recently been shown to have significant anticancer properties. Lisinopril, an inhibitor of the angiotensin system, has been shown to mitigate radiation injuries from low-let exposure. Evaluations will be made on several levels, to include 1) determination of cardiovascular function, 2) identification of cell specific failure, 3) intracellular determination of damage focusing on genomic and mitochondrial DNA damage. Cell failure in terms of metabolic failure, accelerated senescence, as well as DNA damage will be determined. A number of investigations in space biology are currently ongoing at nymc and collaborations and sharing of resources will enhance the research products derived from funding this application. Radiation induced cardiomyopathies are observed months or years after exposure. The present application will separate the insult from the consequences. Our preliminary findings demonstrated significant degradation of cardiac function similar to the accelerated aging phenotype observed with chemotherapy. IT may not be relevant that any single cell dies but that the balance of cell death and cell replacement is upset. Although focused on the heart, these investigations will have widespread application to other organ systems and collectively serve the long term health and well being of flight crews.

Quick answers

Who was awarded contract 80NSSC19K0436?

80NSSC19K0436 was awarded to New York Medical College by Shared Services Center (National Aeronautics and Space Administration) on February 1, 2019.

How much is contract 80NSSC19K0436 worth?

The government has obligated $457,307 on 80NSSC19K0436. Its current value, with exercised options, is $540,200.

Was contract 80NSSC19K0436 competed?

The extent of competition for 80NSSC19K0436 was full and open competition.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award